Henrik Schmidt
Vice President, Commercial - Europe & Apac @Myllia Biotechnology
Signup · Get unlimited contacts
WORK HISTORY
Vice President, Commercial - Europe & Apac @Myllia Biotechnology
Vienna, AT
Myllia Biotechnology is redefining functional genomics by uniting CRISPR-based perturbations, single-cell resolution, and advanced computational modeling. Our platform integrates high-content CRISPR screens with single-cell RNA sequencing in primary human cells to deliver deeply physiologic, mechanistic insights. By generating large-scale, custom perturbation datasets, we enable AI-driven foundation models of virtual cells that infer causal relationships, reveal mechanisms of action, and accelerate unbiased target discovery. This end-to-end approach produces genetically validated, high-value targets for early-stage drug development and generates AI-ready data at a scale and fidelity previously impossible.
EDUCATION
Freie Universität Berlin
Master of Science - MS, Biochemie
Ludwig-Maximilians-Universität München
Dr. rer. nat., Immunology
Max Planck Society
Research Internship, Biochemie
Universität Greifswald
Bachelor of Science - BS, Biochemie
ABOUT HENRIK SCHMIDT
Versatile biotech R&D professional specializing in business development, commercial strategy and long-term collaborations with external biotech and pharma clients. Strong background in biochemistry, immunology, and T cell biology to drive innovative solutions in drug discovery and translational research. Passionate about next-generation gene editing technologies to advance cellular medicines and keen to leverage alliance management skills to support research partnerships in therapeutic areas such as immunology and inflammation (I&I), autoimmune disease and oncology.In my current role as VP, Commercial - Europe & APAC at Myllia Biotechnology I am leading the business development, commercial and external partnership activities with biotech and pharmaceutical companies. At Myllia, we utilize advanced single-cell CRISPR screening workflows in primary human cells to enable unbiased drug target discovery and scalable, AI-ready perturbation data generation for foundation models of human disease biology.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.